Anifrolumab

Generic Name
Anifrolumab
Brand Names
Saphnelo
Drug Type
Biotech
Chemical Formula
-
CAS Number
1326232-46-5
Unique Ingredient Identifier
38RL9AE51Q
Background

Anifrolumab, or MEDI-546, is a type 1 interferon receptor (IFNAR) inhibiting IgG1κ monoclonal antibody indicated in the treatment of adults with moderate to severe systemic lupus erythematosus. The standard therapy for systemic lupus erythematosus consists of antimalarials like hydroxychloroquine, glucocorticoids like dexamethasone, and disease modifying ant...

Indication

Anifrolumab is indicated in the treatment of adults with moderate to severe systemic lupus erythematosus.

Associated Conditions
Moderate Systemic Lupus Erythematosus (SLE), Severe Systemic Lupus Erythematosus (SLE)
Associated Therapies
-
Clinical Trials
Related News

Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus

Not yet recruiting
Conditions
Lupus Erythematosus, Systemic
Interventions
Drug: Anifrolumab
First Posted Date
2024-11-04
Last Posted Date
2024-11-18
Lead Sponsor
AstraZeneca
Target Recruit Count
100
Registration Number
NCT06673043

Pharmacokinetic and Safety Study of Subcutaneous and Intravenous Anifrolumab Delivered in Healthy Adult Participants

Phase 1
Active, not recruiting
Conditions
Healthy Volunteers
Interventions
Drug: Anifrolumab
First Posted Date
2024-10-28
Last Posted Date
2024-12-20
Lead Sponsor
AstraZeneca
Target Recruit Count
24
Registration Number
NCT06662123
Locations
🇨🇳

Research Site, Wuhan, China

Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users

Not yet recruiting
Conditions
Systemic Lupus Erythematosus
Interventions
Drug: Anifrolumab
First Posted Date
2024-10-26
Last Posted Date
2024-10-26
Lead Sponsor
AstraZeneca
Target Recruit Count
442
Registration Number
NCT06659029

Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users

Phase 4
Recruiting
Conditions
Systemic Lupus Erythematosus
Interventions
Drug: Anifrolumab
First Posted Date
2024-09-19
Last Posted Date
2024-12-20
Lead Sponsor
AstraZeneca
Target Recruit Count
16
Registration Number
NCT06594068
Locations
🇺🇸

Research Site, Las Vegas, Nevada, United States

Anifrolumab for Hidradenitis Suppurativa

First Posted Date
2024-04-18
Last Posted Date
2024-07-24
Lead Sponsor
University of North Carolina, Chapel Hill
Target Recruit Count
15
Registration Number
NCT06374212
Locations
🇺🇸

UNC Dermatology and Skin Cancer Center, Chapel Hill, North Carolina, United States

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

First Posted Date
2023-04-28
Last Posted Date
2024-12-09
Lead Sponsor
AstraZeneca
Target Recruit Count
100
Registration Number
NCT05835310
Locations
🇬🇧

Research Site, Southampton, United Kingdom

The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD

First Posted Date
2022-06-30
Last Posted Date
2024-12-06
Lead Sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Target Recruit Count
45
Registration Number
NCT05440422
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Anifrolumab Treatment for 24 Weeks in Patients With Primary Sjögren's Syndrome

Phase 2
Recruiting
Conditions
Sjogren's Syndrome
Interventions
Drug: Placebo
Drug: Anifrolumab
First Posted Date
2022-05-20
Last Posted Date
2022-12-19
Lead Sponsor
University Medical Center Groningen
Target Recruit Count
30
Registration Number
NCT05383677
Locations
🇳🇱

University Medical Centre Groningen, Groningen, Netherlands

Accessorized Pre-Filled Syringe to Autoinjector Pharmacokinetic Bridging Study in Anifrolumab

First Posted Date
2022-04-21
Last Posted Date
2023-05-11
Lead Sponsor
AstraZeneca
Target Recruit Count
180
Registration Number
NCT05339100
Locations
🇬🇧

Research Site, Harrow, United Kingdom

Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis

Phase 3
Recruiting
Conditions
Lupus Nephritis
Interventions
Drug: Anifrolumab
Drug: Placebo
First Posted Date
2021-11-30
Last Posted Date
2024-11-21
Lead Sponsor
AstraZeneca
Target Recruit Count
346
Registration Number
NCT05138133
Locations
🇻🇳

Research Site, Hochiminh, Vietnam

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy